ストックスクリーナーアプリを入手
5.23
2.79%
-0.15
アフターアワーズ：
5.23
前日終値:
$5.38
開ける：
$5.43
24時間の取引高:
182.53K
Relative Volume:
1.15
時価総額：
$290.85M
収益：
$34.16M
当期純損益:
$-98.43M
株価収益率:
-2.235
EPS:
-2.34
ネットキャッシュフロー:
$-119.33M
1週間 パフォーマンス:
-14.68%
1か月 パフォーマンス:
+18.59%
6か月 パフォーマンス:
-29.32%
1年 パフォーマンス:
-12.40%
1日の値動き範囲:
$5.08
$5.54
1週間の範囲:
$5.08
$6.66
52週間の値動き範囲:
$3.86
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
名前
Foghorn Therapeutics Inc
セクター
電話
617-586-3100
住所
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.23 | 290.85M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | 開始されました | B. Riley Securities | Buy |
| 2024-09-03 | 開始されました | Jefferies | Buy |
| 2024-08-19 | 開始されました | Evercore ISI | Outperform |
| 2023-03-28 | 開始されました | BofA Securities | Buy |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-17 | 開始されました | Cowen | Outperform |
| 2020-11-17 | 開始されました | Goldman | Buy |
| 2020-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-17 | 開始されました | Wedbush | Outperform |
すべてを表示
Foghorn Therapeutics Inc (FHTX) 最新ニュース
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health – Company Announcement - Financial Times
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? - MSN
Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace
Eagle financial services executive buys $3,200 in stock - MSN
CENX’s Stock Woes: Up 59.32% in 6 Months, Up 59.32% in Just 5 Days - The InvestChronicle
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Harmony Gold Mining Co Ltd ADR (HMY) Stock: A Study of the Market Performance - The News Heater
Foghorn Therapeutics Inc (FHTX) Shares Up Despite Recent Market Volatility - The News Heater
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks - Markets Insider
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Yahoo Finance
What is B. Riley's Forecast for FHTX FY2024 Earnings? - MarketBeat
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry - Yahoo Finance
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Upgraded by B. Riley - MarketBeat
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated by Analysts at B. Riley - MarketBeat
Why Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025 - Yahoo Finance
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - Yahoo Finance
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains? - Yahoo Finance
Foghorn Therapeutics Advances Drug Development in Oncology - TipRanks
What is B. Riley’s Estimate for FHTX FY2024 Earnings? - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at B. Riley - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at B. Riley - Defense World
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Foghorn Therapeutics a new buy at B Riley on tumor fighting technology - Seeking Alpha
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target -January 30, 2025 at 07:56 am EST - Marketscreener.com
Zevra Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance
Why Akero Therapeutics Inc. (AKRO) Surged on Monday - Yahoo Finance
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On MondayHere's Why - Yahoo Finance
Foghorn Therapeutics receives Nasdaq compliance notice - MSN
Foghorn Therapeutics receives Nasdaq compliance notice By Investing.com - Investing.com Australia
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance
Foghorn Therapeutics (FHTX) Stock Price, News & Analysis - MarketBeat
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation – Company AnnouncementFT.com - Financial Times
Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far In 2025? - Yahoo Finance
Barclays PLC Grows Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week - Yahoo Finance
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR
Foghorn Therapeutics Inc (FHTX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):